Wockhardt Ltd (WOCKPHARMA) — concall transcript | 30 June 2026

Wockhardt's investor call on June 4, 2026, highlighted the US FDA approval of Zaynich, its first India-developed antibiotic, and strategic plans for US and emerging market launches. Management emphasized profitability growth, AI-driven cost initiatives, and expansion of biosimilars and novel antibiotics. Key financials include INR3,373 crores revenue, 51% EBITDA growth, and INR662 crores cash. The company exited loss-making US generics and restructured supply chains. Leadership outlined a focus on scaling Zaynich globally, leveraging biosimilar momentum, and accelerating AI integration. Challenges include high antibiotic resistance rates in India and complex US market entry. The call underscored a shift from survival to scalable growth, with Zaynich positioned as a transformative product addressing critical unmet needs in multi-drug-resistant infections.